Seroquel Lawsuit Response: Keep Pushing Seroquel
AstraZeneca is going to keep pushing Seroquel. Last week AstraZeneca asked the FDA to let it market the antipsychotic drug Seroquel for the treatment of schizophrenia in teenagers and for the treatment of acute manic episodes associated with bipolar I disorder in children and teenagers between 10 and 17.
It is amazing that there are over 13,000 Seroquel lawsuits and AstraZeneca is looking to expand the uses of Seroquel. Currently, two atypical antipsychotics are approved to treat adolescents and the literature to support their use with children is certainly not overwhelming. You have a drug under siege and you try to use that drug for a purpose for which pharmacological efficacy is highly questionable. This is called pushing all of your chips to the center of the table.
In other Seroquel news, About Lawsuits reports that the MDL judge in Orlando, Florida, who is overseeing all federal Seroquel lawsuits, denied a request by AstraZeneca last week to file motions in the Seroquel litigation under seal.
Note: For information on Seroquel class action cases involving diabetes and pancreatitis, click here.
If you think you may have a potential Seroquel lawsuit and have a question about the Seroquel class action lawsuit, you can call one of our Seroquel lawyers for a free consultation at 800-553-8082 or click here for a free Internet Seroquel consultation.
